Gilead eyes PBC expansion for Livdelzi on positive one-year data

Gilead has touted Livdelzi's potential in patients with high ALP levels, potentially expanding the drug’s reach across the PBC indication. Gilead has touted the potential of its liver disease drug in patients with high ALP levels, potentially expanding the drug’s reach across the PBC indication. Gilead’s Livdelzi has demonstrated its efficacy in normalising ALP levels in a Phase III PBC trial. Credit: Julia Kopacheva / Shutterstock.com. Gilead Sciences has debuted 52-week data from a late-stage study on its primary biliary cholangitis (PBC) therapy, Livdelzi (seladelpar), demonstrating the drug’s ability to normalise the levels of a liver enzyme associated with disease…

Source: Clinical Trials Arena